Perspectives in Clinical Pharmacy, Volume 9 Index

acetaminophen, and isoniazid, 7:51
actinomycin C, and second cancers, 1:7
age factors, and drug metabolism, 12:92
AIDS, 4:25, 7:50, 8:59
alcohol dehydrogenase, 6:46–47, 12:91
amiloride in cystic fibrosis, 3:23
anthracyclines, continuous infusion, 5:34
antibiotic therapy, infusion pumps, 5:34
anticonvulsant drugs, 6:42
asthma, 2:9, 3:19

baclofen, 5:35, 8:61
bacteremia, programmable pumps, 5:34
beclomethasone, for asthma, 3:20
beta blockers, 10:78, 12:93
beta-agonists, 3:17–19
beta-adrenergic agonists, 2:12, 3:17
bitolterol, 2:12
bleeding, esophageal variceal, 10:77–79
bone marrow regulation by GM-CSF and G-CSF, 8:57
breast cancer, 5:34, 8:59, 11:83
bronchial fluids, 3:22–23
bronchodilators, 2:10, 14
budesonide, 3:20

candidiasis, and corticosteroids, 3:20
carbamazepine, 4:30, 6:42
catheterization, cardiac, in women, 12:89
cephalosporins, programmable pumps, 5:34
cerebral palsy, spasticity treatment, 8:62
cerebrospinal fluid (CSF), baclofen levels, 8:61
cerebrovascular accidents, and estrogen replacement therapy, 11:85
chemotherapy, 5:33; 8:59
chlorambucil, 1:7
chlordiazepoxide, 12:92
2-chlorodeoxyadenosine, 10:74
chlorofluorocarbons in metered inhalers, 2:10–12
chronic obstructive pulmonary disease (COPD), 2:12; 3:21
cimetidine, 6:45; 7:50
cisplatin, for ovarian cancer, 1:7
clinidine, transdermal, 5:35
codeine, and ethnic differences, 12:93
colony-stimulating growth factors, 8:57–61
contraceptives, 4:31, 6:42
coronary artery disease, 11:85–86
corticosteroids, aerosolized, 3:19–20
creatine phosphokinase, lovastatin effects, 1:5
cromolyn sodium, for asthma, 3:19, 20
cyclophosphamide, 1:7
cyclosporine, 7;50, 55
cystic fibrosis, 3:23, 9:69
cytochrome P-450, 6:41, 7:51
cytotoxicity of fluorouracil, 5:33

dapsone and cimetidine, 7:50–51
daunorubicin, continuous infusion, 5:34
Decapeptyl, 4:31
dermatitis, and transdermal medication, 5:37
dexamethasone for asthma, 3:20
diabetes mellitus, non-insulin-dependent, 1:6; 9:71
diazepam, 12:93
diflunisal, nonlinear pharmacokinetics, 9:66–67
digoxin and quinidine, 6:44–45
disopyramide, enzyme-inducing, 6:42
disulfiram (Antabuse), 12:93
doxorubicin, 1:7, 5:34
doxylamine clearance in women, 12:92
drug absorption, 5:38, 9:71
drug administration, 4:25, 5:33, 6:41
drug evaluation, 10:73
drug therapy, 8:57; 12:92

edema, pulmonary, interleukin-2 therapy, 1:2
encainide and quinidine, 7:52
endocarditis, pumps for antibiotics, 5:34
endometrial carcinoma, 11:82
endometriosis, injectable medication, 4:31
enzymes, drug-metabolizing, 6:41–44
epilepsy, 4:30, 6:43
erythromycin, for diabetes gastroparesis, 9:71
esophageal variceal bleeding, 10:77–79
estradiol, transdermal, 5:35–36
estrogen replacement therapy, 11:82–88
ethanol, 6:41, 7:54, 12:91
ethanolamine oleate, 10:77
ethnic differences, 12:92–95

felodipine and ethanol, 7:54
fenoterol, 2:12, 3:17
fentanyl, transdermal, 5:37
flunisolide, 3:20
fluorouracil, continuous infusion, 5:33–34
flupenthixol decanoate, 4:30
food and drug interactions, 7:54–56
Food and Drug Administration (FDA), 1:1, 2:14, 5:35, 8:58, 10:75, 11:87
furosemide, 3:22, 9:69

ganciclovir and GM-CSF, 8:59
gastrointestinal bleeding, 10:78
gastroparesis, 9:71
gemfibrozil and lovastatin, 1:4–6
gentamicin, programmable pumps, 5:34
glipizide, 9:71
glucuronidation, and drug-metabolizing enzymes, 6:42
gold salts, for asthma, 3:20
granulocyte-colony-stimulating factor (G-CSF), 8:57
grapefruit juice, 7:53
growth factors, hematopoietic, 8:57–61

Halcion, 1:3
haloperidol decanoate, 4:30
head injury, spasticity treatment, 8:61, 63
heart transplantation, ketoconazole and cyclosporine, 7:50
hematopoietic growth factors, 8:57–61
heparin, implantable pumps, 5:35
hepatitis, viral, 10:75–76
Hodgkin's disease, GM-CSF effects, 8:57
human immunodeficiency virus, *Pneumocystis carinii* pneumonia, 4:25
human papilloma virus, 10:74–75
hydralazine, food effects, 7:55
hydrocarbons, polycyclic aromatic, 6:41
hyperglycemia, and drug absorption, 9:71
hypertension, 4:28, 5:35, 6:45, 12:90

immunotherapy, adoptive, 1:1–3
implanted medication, 4:30-32, 8:61–63
indocyanine green, in cystic fibrosis, 9:69
inhalation therapy, 2:9, 3:17
injectables, long-acting, 4:30–32
insomnia, triazolam therapy, 1:3
interferon alfa, 10:73–77
interleukin-2, adverse effects, 1:1–3
intravenous therapy, 5:33–35
ion composition, of bronchial fluid, 3:22–23
ipratropium bromide, 3:21
isoniazid and acetaminophen, 7:51
isoproterenol, for asthma, 3:17
isosorbide mononitrate and propranolol, 10:79

Kaposi's sarcoma, interferon alfa treatment, 10:74
ketoconazole, 1:4, 7:50
ketotifen, for asthma, 3:20
kidney transplantation, cyclosporine and ketoconazole, 7:50
Kostmann's syndrome, 8:60

lazaroids, 8:63
leukemia, 8:57, 9:67
leuprolide absorption, 5:38
levodopa, 4:28, 5:39
levonorgestrel capsules, 4:31
lidocaine metabolism, 9:70–71
lipoproteins, 1:5, 11:85
liver function, 1:4; 9:69
lorazepam, in cystic fibrosis, 69

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685). 1A. Title of publication: Perspectives in Clinical Pharmacy. B. Publication number: 001419. 2. Date of filing: 10/1/91. 3. Frequency of issue: Monthly. A. No. of issues published annually: 12. B. Annual subscription price: $225.00. 4. Complete mailing address of known office of publication: Elsevier Science Publishing Co., Inc., 655 Avenue of the Americas, New York, NY 10010. 5. Complete mailing address of the headquarters of general business offices of the publisher: Elsevier Science Publishing Co., Inc., 655 Avenue of the Americas, New York, NY 10010. 6. Names and complete mailing addresses of publisher, editor and managing editor: Publisher, Elsevier Science Publishing Co., Inc., 655 Avenue of the Americas, New York, NY 10010; Editor, Milo Gibaldi, PhD, University of Washington, School of Pharmacy, Seattle, WA 98195; Managing editor, None. 7. Owner: Elsevier Science Publishing Co., Inc., 655 Avenue of the Americas, New York, NY 10010. 8. Known bondholders, mortgagees, and other security holders owning or holding more than 1% of total amount of bonds, mortgages, or other securities: None. 9. The purpose, function and nonprofit status of this organization and the exempt status for Federal income tax purposes have not changed during preceding 12 months. 10. Extent and nature of circulation: A. Total no. copies (net press run): Average no. copies each issue during preceding 12 months, 814; actual no. copies of single issue published nearest to filing date, 654. B. Paid and/or requested circulation. 1. Sales through dealers and carriers, street vendors and counter sales: None. 2. Mail subscription: Average no. copies each issue during preceding 12 months, 217; actual no. copies of single issue published nearest to filing date, 201. C. Total paid and/or requested circulation: Average no. copies each issue during preceding 12 months, 217; actual no. copies of single issue published nearest to filing date, 201. D. Free distribution by mail, carrier or other means, samples, complimentary, and other free copies: Average no. copies each issue during preceding 12 months, 13; actual no. copies of single issue published nearest to filing date, 18. E. Total distribution: Average no. copies each issue during preceding 12 months, 230; Actual no. copies of single issue published nearest to filing date, 219. F. Copies not distributed. 1. Office use, left over, unaccounted, spoiled after printing: Average no. copies each issue during preceding 12 months, 584; actual no. copies of single issue published nearest to filing date, 435. 2. Return from new agents: None. G. Total: Average no. copies each issue during preceding 12 months, 814; actual no. copies of single issue published nearest to filing date, 654. 11. I certify that the statements made by me above are correct and complete.

Barry Glassberg
Fulfillment Manager

© 1991 by Elsevier Science Publishing Co., Inc.

BEST COPY AVAILABLE

0896–1476/91/$0.00 + 2.20

lovastatin and gemfibrozil, 1:4
luteinizing hormone-releasing hormone, 4:31
lymphokine-activated killer (LAK) cells, and interleukin-2, 1:1–3
lymphoma, non-Hodgkin's, GM-CSF effects, 8:57
melphalan, 1:7
menopause, transdermal estradiol, 5:36
mephenytoin, 12:94
mephobarbital metabolism in women, 12:92
mercaptopurine, 9:67–69
metaproterenol, 2:12, 15
metered dose inhalers, 2:10, 3:17
methotrexate, 1:7, 3:20
3-methyl-O-desmethyl encainide, 7:52–53
methylprednisolone, for spinal cord injury, 8:62
microcapsules, injectable, 4:31
migraine, and gastric emptying, 5:38–39
monocytes, and GM-CSF, 8:57
monoethylglycinexylidide, 9:70–71
morphine pharmacokinetics, 9:65–66
multiple sclerosis, 5:35, 8:61
muscle weakness, lovastatin effects, 1:5
myelodysplastic syndromes, 8:60
myocardial infarction, 11:85; 12:89

naloxone, for spinal cord injury, 8:62
National Acute Spinal Cord Injury Study, 8:62–63
National Cholesterol Education Program, 1:6
nebulizers, 2:10; 4:28
neuroleptic drugs, long-acting injectable, 4:30
neutrophils, and hematopoietic growth factors, 8:57
nicotine, 5:37; 7:53
nicotinic acid hepatotoxicity, 1:6
nifedipine, and ethnic differences, 12:93–94
nitrogen mustard compounds, 1:7
nitroglycerin, 5:35,; 6:47
nizatidine, 6:47
norethisterone, 5:36
Norplant System, 4:31–32

O-desmethyl encainide, 7:52–53
2', 5'-oligoadenylate synthetase, 10:74
omeprazole, nonlinear pharmacokinetics, 9:66–67
Orientals, and drug metabolism, 12:93
osmolarity of bronchial fluid, 3:22
osteomyelitis, home iv antibiotic therapy, 5:34
osteoporosis, 5:36; 11:82
ovarian cancer, 1:7; 5:34
oxycarbazepine, 6:43

penicillin, programmable pumps, 5:34
pentamidine, aerosolized, for PCP, 4:25–28
pentostatin, for hairy-cell leukemia, 10:74
peptides, transdermal, 5:38
pharmacokinetics, 4:30, 6:42, 7:52, 9:69, 12:91
phenobarbital, 6:41
phenytoin, 6:42
physical activity, and transdermal medication, 5:35
pirbuterol, 2:12
plant materials, for pulmonary disease, 3:20–21
portal hypertensive gastropathy, 10:78–79
posture, and transdermal medication, 5:35
potassium, beta-agonist effects, 3:17–18
probenecid and zidovudine, 7:50
procainamide and cimetidine, 7:49
progestagen, and postmenopausal estrogens, 5:36
propafenone and rifampin, 6:42
prophylaxis therapy, 3:18; 4:25; 10:77
propranolol, 6:44, 10:78, 12:91
(+)-4-propyl-9-hydroxynephthoxazine, oral prolonged-release, 4:29
pseudoephedrine and terfenadine, 1:4
pulmonary function, 2:11, 3:20
pumps, infusion, 5:34–35, 8:61

Quinaglute SR, 7:55
quinidine, 6:44; 7:52

ranitidine, 5:39; 6:47
renal cell carcinoma, interleukin-2 effects, 1:1–3
rhabdomyolysis, and lovastatin-gemfibrozil, 1:5
ribavarin, for hepatitis, 10:76
rifampin, enzyme-inducing, 6:41–42

salbutamol, metered dose inhalers, 2:12, 3:17
sargramostim, 8:57
schizophrenia, long-acting injectable medication, 4:30
sclerotherapy, for esophageal variceal bleeding, 10:77–79
scopolamine, transdermal, 5:35
Sinemet CR, 4:29
sleeping medication, 1:3
sodium tetradecyl sulfate, 10:77
spacers, in metered dose inhalers, 2:10–11
stereoselective drugs, 6:44–45
steroids, enzyme-inducing, 6:41–43
stomach, and ethanol metabolism, 6:45–47
stroke, 8:61, 11:61
sulfamethoxazole, in cystic fibrosis, 9:70

tamoxifen, 11:84
terbutaline, in metered dose inhalers, 2:11–12, 3:17–18
terfenadine, 1:3–4
theophylline, 4:28; 9:69
6-thioguanine nucleotides, 9:68
thiopurine methyltransferase, 9:68
tirilazad, 8:63
transdermal medication, 5:35; 11:82
triamcinolone acetonide, 3:20
triglycerides, and nicotinic acid, 1:6
trimethoprim, in cystic fibrosis, 9:70
troleandomycin and terfenadine therapy, 1:4
tumors, carcinoid, interferon alfa treatment, 10:74

uric acid and nicotinic acid, 1:6
urodiolenone, 7:54

valproic acid, 6:43–44
verapamil, 6:45

women, diseases and treatments, 12:89–92
World Health Organization (WHO), hepatitis, 10:76

xanthine oxidase and mercaptopurine, 9:68

zidovudine (AZT), 4:26; 7:50; 8:59; 12:94

General Information

Perpectives in Clinical Pharmacy is published monthly by Elsevier Science Publishing Co., Inc., 655 Avenue of the Americas, New York, NY 10010. Please see inside front cover for subscription information. This newsletter is printed on acid-free paper.

This newsletter has been registered with the Copyright Clearance Center, Inc. Consent is given for copying articles for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition that the copier pay through the Center the per-copy fee stated in the code on the first page for copying beyond that permitted by the US Copyright Law. If no code appears on an article, the author has not been given broad consent to copy and permission to copy must be obtained directly from the author. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

Address orders, changes of address, and claims for missing issues to Journal Fulfillment Department, Elsevier Science Publishing Co., Inc., 655 Avenue of the Americas, New York, NY 10010. Claims for missing issues can be honored only up to three months for domestic addresses and six months for foreign addresses. Duplicate copies will not be sent to replace ones undelivered due to failure to notify Elsevier of change of address.

Address editorial correspondence to Milo Gibaldi, PhD, Dean, School of Pharmacy, Warren G. Magnuson Health Sciences Center, University of Washington, 1959 Pacific, Seattle, WA 98195.

POSTMASTER: Send address changes to *Perspectives in Clinical Pharmacy*, Elsevier Science Publishing Co., Inc., 655 Avenue of the Americas, New York, NY 10010.

Notice: The editor and publisher of this work have made every effort to ensure that the drug dosage schedules herein are accurate and in accord with the standards accepted at the time of publication. Readers are advised, however, to check the product information sheet included in the package of each drug prior to administration to be certain that changes have not been made in the recommended doses or contraindications.

0896–1476/91/$0.00 + 2.20

BEST COPY AVAILABLE

© 1991 by Elsevier Science Publishing Co., Inc.